Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
A single systemic dose of an immune-shielded lentiviral vector delivering the MMUT gene produced lasting metabolic correction in a mouse model of methylmalonic acidemia, according to newly published preclinical data.
Source: CGTLive
Read more →The partners are exploring Avenue Biosciences' signal-peptide engineering with Circio's circVec technology to increase protein expression. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaboration combines Constellation and autoloMATE to address fragmented manufacturing data and process visibility. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners plan to move manufacturing of SBT-77-7101 to Cellares' Cell Shuttle and evaluate automated quality-control testing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The agency has proposed a registration approach for advanced distributed manufacturers using a central quality hub and multiple production units. This is a regulatory or programme announcement; consult the original notice for the precise scope and status.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Fujifilm's Holly Springs manufacturing site was selected as one of the facilities in the FDA's PreCheck pilot programme. This is a regulatory or programme announcement; consult the original notice for the precise scope and status.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →REGENXBIO will receive a $100 million milestone from AbbVie following the first dosing in NAAVIGATE, a pivotal trial evaluating one-time suprachoroidal gene therapy in nonproliferative diabetic retinopathy without center-involved macular edema.
Source: CGTLive
Read more →Shilpa has commissioned an integrated site for manufacturing antibody-drug conjugate drug substance under GMP conditions. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →An independent UK centre reports a continuous bioprocess intended to improve productivity and lower costs for advanced-therapy manufacturing. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Their planned workflow combines capillary isoelectric focusing fractionation and mass photometry to examine bispecific antibodies and biosimilars. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The partners will evaluate automated manufacturing for TScan's TSC-101 as that programme moves toward a planned pivotal study. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced joint development work spanning muscle disease gene therapy and in vivo cell-therapy applications. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
